• Colorectal Cancer Info MAIN MENU
  • Screen MAIN MENU
  • Care MAIN MENU
  • Cure MAIN MENU
  • Get Involved MAIN MENU
  • Our Mission MAIN MENU

Subscribe to the Newsletter

Supporting Innovative Research

The Alliance’s mission is to end colorectal cancer in our lifetime. By supporting innovative colorectal cancer research by top doctors and scientists, we take important steps toward realizing our vision — a world free of this disease.

Click on a type of research below to see who is using our funding to accelerate treatment, prevention, and a cure. 

Research Focus: Health Disparities

Dr. Kishore Guda, Case Comprehensive Cancer Center

Decoding Molecular Programs Contributing to Colorectal Cancer Disparities

Study Description: Dr. Kishore Guda aims to characterize the molecular profiles of colorectal cancers in African American versus European American patients. Using relevant cancer cell patient samples along with mouse models in the laboratory, the team will discover and validate biologic mechanisms likely contributing to colorectal cancer health disparities. Importantly, the study is designed to decode the role of tumor biology as well as socio-demographic factors that jointly contribute to racial disparities in colorectal cancer outcomes. Overall, their studies will inform the development of new biomarkers and therapeutic strategies with the overarching goal of improving health equity in colorectal cancer.

Francisco Sanchez-Vega, PhD - Memorial Sloan Kettering Cancer Center

Leveraging race-informed biological models for disparities research in CRC

Study Description: Dr. Sanchez-Vega will investigate whether the higher colorectal cancer incidence and mortality of non-Hispanic Black (NHB) patients vs. non-Hispanic White patients is driven by differences in cancer biology, socioeconomic conditions, or other factors. His team will establish a unique biorepository of patient-derived organoid (PDO) models from NHB CRC patients. Existing CRC organoid biobanks have not included race, so there are not any well-characterized PDO models derived from NHB patients. New models will enable real-time validation of genomic predictions, testing of therapeutic options, and clarification of race-specific mechanisms of tumor progression and therapy resistance. The ultimate goal is to identify opportunities to intervene and improve outcomes in the NHB population.

2022 Chris4Life Colorectal Cancer Alliance Early Career Investigator Award

Latest Updates

Upcoming Events

Are you sure?

Clicking "Start Over" will empty your resources drawer and take you back to the beginning of the journey customizer. Would you like to continue?

Are you sure?

Clicking "Exit" will permanently close your resource drawer for the rest of the session. If you would like to minimize the drawer and access it from other pages, click the symbol next to "MY RESOURCES". Would you like to permanently exit the drawer?